Finance

Roʻyxatlar
EW:NYSE
Edwards Lifesciences Corp
83,77 US$
-0,61%
(-0,51) 1K
9-okt, 13:42:28 (GMT-4)  ·   USD
Barcha belgilar
BelgiNarxiOʻzgartirishlarDinamika (%)
EW tikeri uchun statistika yaratilmoqda...
Ochish
84,60 US$
Yuqori
85,34 US$
Past
83,22 US$
Bozor kapitali
48,29 mlrd
Oʻrtacha hajm
3,43 mln
Hajmi
1,61 mln
P/E koeffitsiyenti
48,46
52 haftalik eng yuqori
96,29 US$
52 haftalik eng past
72,30 US$
Aksiya boʻyicha daromad
1,73 US$
Beta
0,87
Muomaladagi aksiyalar
576,40 mln
Xodimlar soni
16 ming
Ochish
84,60 US$
Yuqori
85,34 US$
Past
83,22 US$
Bozor kapitali
48,29 mlrd
Oʻrtacha hajm
3,43 mln
Hajmi
1,61 mln
P/E koeffitsiyenti
48,46
52 haftalik eng yuqori
96,29 US$
52 haftalik eng past
72,30 US$
Aksiya boʻyicha daromad
1,73 US$
Beta
0,87
Muomaladagi aksiyalar
576,40 mln
Xodimlar soni
16 ming
Yangiliklar
Internet manbalari va yangilik hamkorlarimizdan
Profil
Edwards Lifesciences Corporation is an American medical technology company headquartered in Irvine, California, specializing in tissue heart valves and transcatheter technologies for the treatment of structural heart disease. The company has manufacturing facilities at the Irvine headquarters, as well as in Draper, Utah; Costa Rica; Singapore; and Limerick, Ireland. The company is also constructing a manufacturing plant in Moncada, near Valencia, Spain, with a €150 million investment. Production is scheduled to begin in 2027. Wikipedia
Edwards Lifesciences Corp haqida
CEO-
Xodimlar soni16 ming
Asos solingan1958
Bosh ofislarIrvayn, Kaliforniya, Amerika Qo‘shma Shtatlari
Sektor-
Veb-saytedwards.com
Analitik reytinglar
Oxirgi 3 oyda EW aksiyalari boʻyicha reyting bergan 16 tahlilchi xulosasiga koʻra
Sotib olish tavsiya etiladi
Sotib olish
13
Ushlab qolish
3
Sotish
0
12 oylik prognoz
Oxirgi 3 oyda EW uchun 12 oylik narx maqsadlarini taklif qilgan 16 Wall Street tahlilchisi xulosasiga koʻra
Eng yuqori
Joriy 83,77 US$
110,00 US$ (+31,31%)
O‘rtacha
104,00 US$ (+24,15%)
Eng past
85,00 US$ (+1,47%)
Analitik
Tavsiya
Amal
Kutilayotgan narx
Prognoz
Sana
Patrick Wood
UBS
Buy
Maintained
110,00 US$
+31,3%
10/07/2026
Matt Miksic
Barclays
Buy
Maintained
110,00 US$
+31,3%
10/07/2026
Tycho Peterson
Jefferies
Buy
Initiated
110,00 US$
+31,3%
10/07/2026
Joanne Wuensch
Citi
Buy
Maintained
110,00 US$
+31,3%
10/05/2026
Kendall Au
RBC Capital
Buy
Maintained
110,00 US$
+31,3%
10/01/2026
Mike Kratky
Leerink Partners
Buy
Reiterated
101,00 US$
+20,6%
09/28/2026
Adam Maeder
Piper Sandler
Buy
Maintained
101,00 US$
+20,6%
09/21/2026
Matthew Taylor
Jefferies
Buy
Maintained
105,00 US$
+25,3%
09/11/2026
Marie Thibault
BTIG
Buy
Maintained
110,00 US$
+31,3%
09/10/2026
Brandon Vazquez
William Blair
Buy
Maintained
-
-
09/10/2026
William Plovanic
Canaccord Genuity
Hold
Maintained
85,00 US$
+1,5%
08/03/2026
Robbie Marcus
J.P. Morgan
Buy
Maintained
105,00 US$
+25,3%
07/28/2026
Rick Wise
Stifel Nicolaus
Buy
Maintained
110,00 US$
+31,3%
07/24/2026
Suraj Kalia
Oppenheimer
Hold
Maintained
-
-
07/24/2026
Richard Newitter
Truist Financial
Hold
Reiterated
95,00 US$
+13,4%
07/24/2026
Shagun Singh Chadha
RBC Capital
Buy
Reiterated
110,00 US$
+31,3%
07/23/2026
Travis Steed
Bank of America Securities
Buy
Maintained
100,00 US$
+19,4%
07/21/2026
Josh Jennings
TD Cowen
Buy
Reiterated
104,00 US$
+24,1%
07/23/2026
Anthony Petrone
Mizuho Securities
Buy
Maintained
105,00 US$
+25,3%
07/15/2026
Vijay Kumar
Evercore ISI
Buy
Maintained
100,00 US$
+19,4%
07/06/2026
David Roman
Goldman Sachs
Buy
Maintained
98,00 US$
+17%
06/15/2026
Krish Sankar
TD Cowen
Buy
Reiterated
104,00 US$
+24,1%
06/02/2026
David Toung
Argus Research
Buy
Maintained
-
-
05/21/2026
David Rescott
Robert W. Baird
Hold
Maintained
87,00 US$
+3,9%
04/24/2026
Michael Polark
Wolfe Research
Buy
Upgraded
92,00 US$
+9,8%
04/01/2026
Danielle Antalffy
UBS
Hold
Maintained
90,00 US$
+7,4%
02/12/2026
Larry Biegelsen
Wells Fargo
Buy
Reiterated
100,00 US$
+19,4%
02/11/2026
Oxirgi hisobot
23-iyl, 2026
Moliya davri
Ch.2 2026
0,78 US$ / 0,74 US$
+5,11%musbat
Taxminiy daromad (USD)
1,74 mlrd / 1,70 mlrd
+2,44%musbat
Q2 2026 uchun tushumlar hisoboti
Tushumlar hisoboti kutilmoqda
Qisqacha
Oxirgi yangiliklar va hisobotlar sarhisobi
Avvalgi hisobotlarBarcha qiymatlar – USD
Loading Previous Earnings...
Daromad
Sof foyda
Barcha qiymatlar – USD
sen, 2025
dek, 2025
mar, 2026
iyn, 2026
Daromad
1,55 mlrd
1,57 mlrd
1,65 mlrd
1,74 mlrd
Sotilgan mahsulotning tannarxi
345,20 mln
343,00 mln
362,60 mln
392,40 mln
Daromad narxi
345,20 mln
343,00 mln
362,60 mln
392,40 mln
Tadqiqot va ishlanmalarga xarajatlar
280,70 mln
267,70 mln
263,30 mln
278,90 mln
Tadqiqot va ishlanmalarga xarajatlar jami xarajatlar
-
-
-
-
Tijoriy, umumiy va maʼmuriy xarajatlar
514,60 mln
601,20 mln
522,20 mln
561,20 mln
Operatsion xarajatlar
782,80 mln
854,60 mln
771,30 mln
829,10 mln
Jami operatsion xarajatlar
1,13 mlrd
1,20 mlrd
1,13 mlrd
1,22 mlrd
Operatsion daromad
425,10 mln
372,00 mln
514,70 mln
519,50 mln
Boshqa nooperatsion daromad
1,10 mln
2,30 mln
69,90 mln
-25,00 mln
Soliq toʻlangunga qadar foyda, shu jumladan gʻayrioddiy moddalar
348,40 mln
90,40 mln
459,00 mln
519,80 mln
Soliq toʻlangunga qadar foyda, gʻayrioddiy moddalar bundan mustasno
444,50 mln
464,00 mln
603,60 mln
511,10 mln
Daromad soligʻi boʻyicha xarajat
56,10 mln
26,20 mln
78,30 mln
278,40 mln
Amaldagi soliq stavkasi
16,10%
28,98%
17,06%
53,56%
Boshqa operatsion xarajatlar
-12,50 mln
-14,30 mln
-14,20 mln
-11,00 mln
Sof foyda
291,10 mln
91,20 mln
380,70 mln
241,90 mln
Sof foyda marjasi
18,74%
5,81%
23,09%
13,89%
Har bir aksiya foydasi
0,67
0,58
0,78
0,78
Foizlar va investitsiyalardan olingan daromadlar
16,70 mln
114,20 mln
17,40 mln
15,00 mln
Foizlarni toʻlash xarajatlari
-
-20,40 mln
-
-
Foizlarni toʻlash boʻyicha sof xarajatlar
16,70 mln
93,80 mln
17,40 mln
15,00 mln
Amortizatsiya ajratmalari
-
-
-
-
EBITDA
464,30 mln
414,70 mln
555,60 mln
562,20 mln
Aktivlarni sotishdan olingan foyda yoki zarar
-
-33,90 mln
-
-
Insayder tranzaksiyalari
Insayder tranzaksiyalari maʼlumotlari tashqi manbalardan olingan. Batafsil
Insayder
Joylashuvi
Turi
Sana
Aksiyalar
Miqdor
1-sahifa
AI kontentda xatolar boʻlishi mumkin. Batafsil
Google ilovalari